Drug Profile
Research programme: T cell receptor-based cancer therapeutics - Bellicum Pharmaceuticals/Leiden University Medical Center
Alternative Names: High-affinity T cell receptor product candidates - Bellicum Pharmaceuticals/LUMC; TCR cell therapies - Bellicum Pharmaceuticals/LUMC; TCRs - Bellicum Pharmaceuticals/Leiden University Medical CenterLatest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Bellicum Pharmaceuticals; Leiden University Medical Center
- Developer Leiden University Medical Center
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Feb 2024 Discontinued for Cancer in Netherlands (Parenteral) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
- 28 Jul 2020 No recent reports of development identified for research development in Cancer in Netherlands (Parenteral)
- 02 Jun 2016 Bellicum Pharmaceuticals and Leiden University Medical Center agree to co-develop T cell receptor-based therapeutics in Netherlands for Cancer